Vertex Pharmaceuticals

VRTX | NASDAQ

Price Alert Chart Builder DCF Calculator

$509.84

+$1.50 (+0.30%)

Sep 21, 2026, 11:21 AM ET · Market open

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

Pro Subscription

Upgrade now for unlimited access to all data, tools and no ads.

Upgrade now ➞

Related Stocks

Company	Yield
ARGX argenx SE	N/A
BMY Bristol-Myers Squibb Company	3.98%
CVS CVS Health	2.99%
GSK GSK plc	3.62%
HCA HCA Healthcare	0.72%
MCK McKesson	0.39%
MDT Medtronic plc	3.09%
REGN Regeneron Pharmaceuticals	0.47%
SNY Sanofi	5.70%
SYK Stryker	1.26%

Dividend Rankings ➞

Recent News

2 days ago / zacks.com
Vertex Pharmaceuticals (VRTX) Stock Sinks As Market Gains: Here's Why
7 days ago / seekingalpha.com
Vertex Pharmaceuticals Incorporated (VRTX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
11 days ago / seekingalpha.com
Vertex Pharmaceuticals Incorporated (VRTX) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript
11 days ago / seekingalpha.com
Vertex Pharmaceuticals Incorporated (VRTX) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
13 days ago / zacks.com
Vertex Pharmaceuticals (VRTX) Suffers a Larger Drop Than the General Market: Key Insights
13 days ago / zacks.com
Investors Heavily Search Vertex Pharmaceuticals Incorporated (VRTX): Here is What You Need to Know
19 days ago / zacks.com
Why Is Vertex (VRTX) Up 14.4% Since Last Earnings Report?
1 month ago / defenseworld.net
AssuredPartners Investment Advisors LLC Invests $2.06 Million in Vertex Pharmaceuticals Incorporated $VRTX
2 months ago / zacks.com
VRTX's Q2 Earnings Lag Estimates, Revenues Top, 2026 Sales View Raised
2 months ago / zacks.com
VRTX Q2 Earnings Call Highlights Launch Momentum & Higher Outlook